U.S. Food Stock News

NasdaqGM:BZAI
NasdaqGM:BZAISemiconductor

Assessing Blaize Holdings (BZAI) Valuation After New Edge AI Partnerships And Rising Investor Interest

Blaize Holdings (BZAI) has moved into the spotlight after filing a follow-on equity offering, shortly after announcing partnerships with Winmate, Nokia, and Datacomm focused on rugged edge AI systems and regional AI infrastructure. See our latest analysis for Blaize Holdings. The stock has attracted fresh attention around these AI partnerships, with a 90 day share price return of 110% and a 30 day gain of 23.53%. However, the 1 year total shareholder return is negative at 8.33%, and the 3...
NYSE:XYZ
NYSE:XYZDiversified Financial

Bank of America’s AI-Focused Coverage Could Be A Game Changer For Block’s Workforce Strategy (SQ)

In late April 2026, Bank of America Securities began covering Block, highlighting the company’s AI-driven workforce reshaping and operational efficiency focus across Square and Cash App. This coverage underscores how Block’s push into automation and cost discipline is becoming central to how some analysts assess its long-term business profile. Next, we’ll examine how this emphasis on AI-enabled efficiency and workforce reset could influence Block’s existing investment narrative. The best AI...
NYSE:HIG
NYSE:HIGInsurance

Assessing Hartford (HIG) Valuation After Recent Mixed Short Term Share Price Moves

Why Hartford Insurance Group (HIG) Is On Investors’ Radar Today Hartford Insurance Group (HIG) is drawing attention after recent trading left the stock with mixed short term returns, including a 0.3% gain over the past day and declines over the past week and month. See our latest analysis for Hartford Insurance Group. The recent 1 day share price return of 0.25% to US$134.15 comes after weaker momentum over the past quarter. The 1 year total shareholder return of 7.76% sits against very...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

A Look At Vistance Networks (VISN) Valuation After Recent Volatility In Share Performance

What recent performance says about Vistance Networks stock With no single headline event driving attention, Vistance Networks (VISN) has drawn investor interest after a mixed stretch, with a 24.0% gain over the past week but double digit declines over the month and past 3 months. The stock last closed at $12.28, with recent returns contrasting sharply with its longer term total returns, which sit in the low to mid single digits over 1, 3, and 5 years. See our latest analysis for Vistance...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

Is It Too Late To Consider Extreme Networks (EXTR) After A 67% One-Year Surge?

Wondering if Extreme Networks at US$23.71 is starting to look expensive or if there is still value on the table? This article breaks down what the current price really implies. The stock has moved sharply, with returns of 39.1% over the past week, 54.4% over the past month, 43.3% year to date and 67.1% over the past year. This can change how you think about both opportunity and risk. Recent coverage has focused on Extreme Networks as a technology stock that has attracted more attention...
NYSE:HCA
NYSE:HCAHealthcare

Is It Time To Reconsider HCA Healthcare (HCA) After The Recent Share Price Pullback

Wondering if HCA Healthcare at around US$428.79 is still offering value, or if most of the opportunity is already reflected in the price. The stock has seen a 9.1% decline over the last 30 days and is down 8.8% year to date, yet it has delivered a 21.0% return over 1 year and 116.3% over 5 years. Recent coverage has focused on how a large hospital operator like HCA Healthcare fits into investors' views on healthcare spending and hospital capacity. There has been attention on how its scale...
NasdaqGS:SRAD
NasdaqGS:SRADHospitality

Sportradar Group (SRAD) Is Up 8.7% After Share Buyback, Legal Scrutiny, and New COO Hire

Sportradar Group AG recently reported first-quarter 2026 sales of €346.52 million with a net loss of €6.29 million, completed a US$228 million share repurchase program covering 12,500,000 shares, and earlier alleged misconduct has prompted multiple law firms to investigate its disclosures and relationships with unlicensed gambling operators. Against this backdrop, the company has appointed former Entain executive Sameer Deen as Chief Operating Officer, signaling a focus on tightening...
NYSE:NEU
NYSE:NEUChemicals

A Look At NewMarket (NEU) Valuation After Softer Q1 Earnings Dividend And Buyback Update

Earnings, dividend and buyback update shape NewMarket’s latest move NewMarket (NEU) has put several key pieces on the table at once by reporting first quarter results, declaring a US$3.00 per share dividend, and updating investors on recent share repurchases. See our latest analysis for NewMarket. Those earnings, dividend and buyback updates come after a mixed stretch in the stock, with a 1 month share price return of 8.14% and a 90 day share price return of 4.11%. The 5 year total...
NYSE:EFC
NYSE:EFCMortgage REITs

Will Ellington Financial's (EFC) Big Q1 2026 Earnings Beat Redefine Its Profitability Narrative

Ellington Financial Inc. has reported past first-quarter 2026 results, posting net income of US$105.32 million and basic and diluted earnings per share from continuing operations of US$0.78. This outcome compared with pre-announcement expectations for earnings per share of US$0.49, highlighting materially stronger profitability than analysts had anticipated. With earnings per share comfortably above prior forecasts, we’ll now examine how this surprise shapes Ellington Financial’s broader...
NYSE:BCO
NYSE:BCOCommercial Services

A Look At Brink's (BCO) Valuation As Shares Lag Intrinsic Value Estimates

With no single headline event setting the tone, Brink's (BCO) is drawing attention as investors weigh its recent share price moves in relation to its current fundamentals and performance across cash management and security services. See our latest analysis for Brink's. Brink's recent share price has eased back, with a 7 day share price return of 4.1% and a 90 day share price return showing an 18.9% decline. Longer term momentum remains stronger, reflected in a 1 year total shareholder return...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Is It Too Late To Consider Harrow (HROW) After Its Recent Share Price Surge

Wondering whether Harrow at US$40.50 still offers value, or if most of the opportunity is already priced in? This article is built to help you frame that question clearly. The stock has returned 14.7% over the past 30 days, sits on a 67.9% return over 1 year, but is still down 18.9% year to date. This raises fair questions about both upside potential and risk. Recent coverage has focused on Harrow's position in the pharmaceuticals space and how investors are reacting to its latest...
NasdaqGS:FSTR
NasdaqGS:FSTRMachinery

L.B. Foster (FSTR) Margin Compression To 2% Tests Bullish Earnings Narratives

Q1 2026 earnings snapshot L.B. Foster (FSTR) opened 2026 with Q1 revenue of US$121.1 million and basic EPS of US$0.15, alongside net income of US$1.5 million, setting a measured tone for the latest earnings season update. Over the past year, the company has seen revenue move from US$504.2 million on a trailing twelve month basis to US$563.4 million, while trailing EPS shifted from US$3.41 to US$1.08, giving investors a mixed picture as they assess how much of the recent margin pressure is...
NasdaqCM:LIND
NasdaqCM:LINDHospitality

Lindblad Expeditions Holdings (LIND) Losses And Negative Equity Test Bullish Turnaround Narrative

Latest results set the stage for Lindblad Expeditions Holdings (LIND) narrative check Lindblad Expeditions Holdings (LIND) has just opened Q1 2026 earnings season with recent quarterly revenue between US$167.9 million and US$240.2 million and EPS fluctuating from a small loss of US$0.0008 per share to a deeper quarterly loss of US$0.48 over the past year, capped by trailing twelve month EPS of US$0.63 in losses on US$771.0 million of revenue. Over that same stretch, net income moved between a...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

Has T. Rowe Price (TROW) Rebound Left More Room For Upside?

If you are wondering whether T. Rowe Price Group at around US$104 a share offers fair value or a potential bargain, this article walks through the key numbers so you can judge it for yourself. The stock has returned 3.3% over the last week and 15.5% over the last 30 days, while the 1-year return sits at 21.7% and the 5-year return at a 29.2% decline. This can raise questions about how the current price lines up with fundamentals. Recent coverage has focused on how T. Rowe Price Group is...
NYSE:AIG
NYSE:AIGInsurance

Is It Too Late To Reassess AIG (AIG) After Recent Insurance Sector Interest?

Investors may be wondering whether American International Group at around US$78 still offers value or if most of the opportunity is already priced in. The stock recently closed at US$78.47, with returns of 5.8% over 7 days and 4.0% over 30 days. Year to date it shows a 6.9% decline and a 2.8% decline over 1 year, compared with gains of 57.9% over 3 years and 74.4% over 5 years. Recent news has highlighted ongoing interest in large insurers as investors reassess sector risk and capital...
NasdaqGS:WSFS
NasdaqGS:WSFSBanks

WSFS Financial (WSFS) Net Interest Margin Steady In Q1 2026 Challenges Big Efficiency Hopes

WSFS Financial (WSFS) has kicked off Q1 2026 with total revenue of US$277.2 million and basic EPS of US$1.64, backed by net income of US$86.8 million. Over recent quarters, revenue has moved from US$238.8 million and EPS of US$1.13 in Q1 2025 to US$259.2 million and EPS of US$1.34 in Q4 2025, before reaching the latest Q1 2026 levels. With a net interest margin of 3.83% and trailing net profit margins previously characterized as improving, this set of results gives investors a clear,...
NYSE:ABBV
NYSE:ABBVBiotechs

AbbVie Expands SKYRIZI Access As Immunology And Dividend Story Evolves

AbbVie (NYSE:ABBV) is expanding access to SKYRIZI for ulcerative colitis patients in Canada through new formulary listings and positive reimbursement recommendations. The company is presenting new clinical outcome data for SKYRIZI and RINVOQ in inflammatory bowel diseases. AbbVie is extending the commercial and clinical reach of its immunology portfolio while pursuing digital transformation efforts in life sciences. For investors watching NYSE:ABBV, these updates highlight fresh activity in...
NasdaqGM:GHRS
NasdaqGM:GHRSPharmaceuticals

Why GH Research (GHRS) Is Up 7.2% After $117.5 Million Follow-On Equity Raise - And What's Next

GH Research PLC recently completed a follow-on equity offering of 6,527,779 common shares at US$18.00 each, raising about US$117.50 million to support its depression treatment pipeline and broader corporate needs. This capital raise underscores investor interest in GH Research’s efforts to develop therapies for treatment-resistant depression, potentially strengthening its clinical and pre-commercialization capabilities. We’ll now explore how this sizeable capital injection to fund GH...
NYSE:AHRT
NYSE:AHRTREITs

Undervalued Small Caps With Insider Buying To Consider In May 2026

The United States market has seen a robust performance recently, climbing 1.8% in the last week and 30% over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying small-cap stocks that are perceived as undervalued and have insider buying can provide unique opportunities for investors seeking potential growth.
NYSE:WMB
NYSE:WMBOil and Gas

3 Stocks Estimated To Be Priced Below Intrinsic Value In May 2026

The United States market has shown robust performance, climbing 1.8% in the last week and achieving a 30% increase over the past year, with earnings expected to grow by 16% annually. In this thriving environment, identifying stocks that are priced below their intrinsic value can offer investors opportunities for potential gains while maintaining a focus on fundamental strengths and growth prospects.